OTCMKTS:ANTH Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis $0.0001 +0.00 (+∞) As of 09/12/2025 12:04 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsShort InterestBuy This Stock About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ANTH alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0002Volume785 shsAverage Volume247 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Anthera Pharmaceuticals, trading on the OTC Markets under the symbol ANTH, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for patients suffering from serious and rare inflammatory and autoimmune diseases. The company’s research and development efforts center on both biologic and small-molecule approaches designed to modulate key pathways in immune system dysfunction. Anthera’s strategy includes advancing lead candidates through late-stage clinical trials while exploring additional indications for its pipeline assets. The company’s most advanced asset, blisibimod, is a selective antagonist of B-cell activating factor (BAFF) that has been evaluated in clinical studies for systemic lupus erythematosus (SLE) and primary immune thrombocytopenia (ITP). Anthera has also pursued early-stage programs in fibrotic conditions and cardiovascular diseases, leveraging its proprietary protein engineering platform to generate novel candidates with potential best-in-class attributes. Collaboration agreements with academic institutions and contract research organizations support Anthera’s efforts to accelerate development timelines and broaden the clinical assessment of its technologies. Founded in the mid-2000s and headquartered in Hayward, California, Anthera has conducted multi-center trials across North America and Europe. The company’s management team comprises professionals with extensive experience in immunology, clinical operations and regulatory affairs, reflecting a commitment to rigorous clinical development and systematic advancement of its pipeline. Anthera’s operations include in-house research capabilities as well as strategic partnerships aimed at bridging the gap between laboratory discovery and commercial availability for patients in need.AI Generated. May Contain Errors. Read More Receive ANTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANTH Stock News HeadlinesANTH Anthera Pharmaceuticals, Inc.April 24, 2025 | seekingalpha.comMACK - Merrimack Pharmaceuticals, Inc.June 28, 2023 | finance.yahoo.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.September 15 at 2:00 AM | Porter & Company (Ad)Industry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030May 16, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 ForecastMay 16, 2023 | marketwatch.com2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]May 5, 2023 | marketwatch.com2023-2030 Gaucher Disease Treatment Market Size (Growth and Outlook) includes Company Information | with [104 Pages]May 4, 2023 | marketwatch.comGaucher Disease Treatment Market Top Key Players by 2030April 28, 2023 | marketwatch.comSee More Headlines ANTH Stock Analysis - Frequently Asked Questions How have ANTH shares performed this year? Anthera Pharmaceuticals' stock was trading at $0.0001 at the beginning of the year. Since then, ANTH stock has increased by 0.0% and is now trading at $0.0001. How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) posted its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.09. When did Anthera Pharmaceuticals' stock split? Anthera Pharmaceuticals shares reverse split before market open on Monday, May 1st 2017.The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Arena Pharmaceuticals (ARNA), Bristol Myers Squibb (BMY), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings3/05/2018Today9/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ANTH CIK1316175 Webwww.anthera.com Phone(410) 350-1839Fax510-856-5597Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.86 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:ANTH) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anthera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anthera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.